Plant Polysaccharide Fraction for C. Difficile Toxin Neutralization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Clostridium difficile infections, including antibiotics, probiotics, monoclonal antibodies, and fecal transplantation, are ineffective in preventing relapses and often cause side effects, while existing toxin-binding therapies are immunogenic or costly.

Innovation Solution

An insoluble polysaccharide fraction obtained from plant cells cultured in suspension, enriched with natural molecules, is used to bind and inactivate Clostridium difficile toxins A and B, preventing infection and recurrence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotic therapy (metronidazole or vancomycin) is administered to treat C. difficile infection, then the acute infection is resolved, but intestinal dysbiosis is aggravated and relapse incidence increases

Engineering Contradiction:

Improveinfection resolutionVSAvoidintestinal dysbiosis and relapse

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces an intermediary substance (polysaccharide preparation from plant cell cultures) that mediates between the antibiotic treatment and the intestinal microbiota. This preparation binds to C. difficile toxins and serves as a protective agent, allowing antibiotic therapy to resolve acute infection while the polysaccharides prevent toxin-mediated damage and support microbiota recovery, thereby reducing relapse risk

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful effect of antibiotics (which cause dysbiosis) into a beneficial outcome by introducing a preparatory substance that protects against the harmful consequences. The polysaccharide preparation binds to toxins and protects intestinal cells, transforming the situation where antibiotics cause harm into a scenario where they can effectively treat infection while the preparation mitigates the harmful side effects

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If monoclonal antibody therapies are used to neutralize toxins, then toxin binding and protection is achieved, but significant side effects and high cost occur

Engineering Contradiction:

Improvetoxin neutralizationVSAvoidside effects and cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces expensive monoclonal antibodies with a cheaper alternative: polysaccharide preparations from plant cell cultures. These polysaccharides perform the essential function of toxin binding and neutralization but are significantly less expensive to produce and administer, making the therapy accessible to a broader patient population without compromising the core protective function

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the fundamental parameter of the binding agent from protein-based (monoclonal antibodies) to carbohydrate-based (polysaccharides). This parameter change maintains the essential function of toxin binding while dramatically reducing cost and side effect profile, as polysaccharides are naturally occurring, biocompatible substances with different immunogenic properties compared to monoclonal antibodies

Inventive Principle:

Principle #35Parameter changes

3Stability of the object's composition

If fecal transplantation is performed to restore microbiota, then microbiota reconstitution is achieved, but the procedure is invasive, expensive, and risky

Engineering Contradiction:

Improvemicrobiota balanceVSAvoidprocedure invasiveness

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the beneficial protective components (polysaccharides) from plant cell cultures, separating them from the complex fecal material. This extraction creates a purified, standardized preparation that can be administered orally without the invasiveness of fecal transplantation, while still providing the protective effects needed to restore microbiota balance and prevent C. difficile recurrence

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent creates a simplified copy or model of the protective effect achieved by fecal transplantation. Instead of administering entire fecal matter, the invention uses polysaccharide preparations that replicate the essential protective function (toxin binding and microbiota support) in a much simpler, safer, and more controllable form

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The insoluble polysaccharide fraction effectively neutralizes toxins in vitro and in vivo, reducing intestinal damage and preventing weight loss in infected animals, offering a safe and effective treatment for primary and recurrent infections.

Implementation Method 1

an insoluble preparation of plant polysaccharides for use in binding the toxins produced by Clostridium difficile

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUS12629402B2Preparation of insoluble polysaccharides obtained from plant cell cultures in suspension for the treatment of clostridium difficile infections

Publication Date: 2026.05.19 ABRES SRL

AI summary

An insoluble cell fraction obtained from plant cells cultured in a suspension composed entirely of natural molecules for the treatment of primary and recurrent Clostridium difficile infections is provided. A process for the preparation of the insoluble cell fraction is also provided.